DIAGNOS Announces Closing of Private Placement

DIAGNOS Inc. (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, has announced the closing of a non-brokered private placement of 5,228,668 units at a price of $0.30 per unit, raising gross proceeds of $1,568,600.40. The private placement was completed on October 25, 2024, and the net proceeds will be used to fund product development and commercialization of AI-based screening services, regulatory affairs, and general and administrative operations.

Each unit consists of one common share and one common share warrant, with each warrant exercisable to purchase one share at a price of $0.40 per share for a period of 18 months ending April 25, 2026. In connection with the closing of the private placement, the Corporation paid cash commissions amounting to $18,207 and issued an aggregate number of 60,690 finder’s warrants to three qualified firms acting at arm’s length to the Corporation. Each finder’s warrant entitles the holder to purchase one share at an exercise price of $0.40 per share for a period of 18 months ending April 25, 2026.

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis), which provides sharper, clearer, and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.



The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation. All monies quoted in this press release shall be stated and paid in lawful money of Canada.

In conclusion, DIAGNOS' private placement is a strategic move to fund its growth and expansion in the early detection of critical health issues using AI technologies. The successful closing of the private placement will enable the company to invest in product development, commercialization, and operational expenses, positioning it for future growth and success in the competitive healthcare technology market.